Pyrazinamide
Brand: PZA (global) / Zinamide (IN) / Pyrazide (BD)
Antibiotic
Anti-TB (nicotinamide analog)
Pharmacokinetics
| Half-life | 9.5 hours |
| Tmax | 2 h |
| Bioavailability | 90 % (approx) |
| Protein Binding | 10 % |
| Volume of Distribution | 0.6 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Weight-based dosing in practice; hepatotoxic with other TB drugs—monitor LFTs. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Hepatotoxicity, hyperuricemia → gout flares, GI upset
Contraindications:
Severe hepatic disease, acute gout
Precautions:
Monitor LFTs and uric acid; manage gout symptoms if needed